

AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

Release: 5/19/2022 8:00:00 AM

OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- **AIM ImmunoTech Inc. (NYSE: American AIM)** ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that [Thomas K. Equels, M.S. J.D., Chief Executive Officer](#) of AIM, will present at the [H.C. Wainwright Global Investment Conference](#) being held May 23-26, 2022 in Miami, FL and virtually.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the [conference website](#).

A [video webcast](#) of the presentation will be accessible for viewing on-demand beginning on Tuesday, May 24, 2022, at 7:00 AM ET for those registered for the event and will be available on the [Events](#) page in the Investor Relations section of the Company's website ([aimimmuno.com](#)). The webcast replay will be archived for 90 days following the event.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company's lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

Ampligen is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM plans to initiate a Phase 2 clinical study in 2022. The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. Additionally, Ampligen is approved in Argentina for the treatment of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and is currently being evaluated for SARS-CoV-2 and COVID-19 Long Hauler.

For more information, please visit [aimimmuno.com](#) and connect with the Company on [Twitter](#), [LinkedIn](#), and [Facebook](#).

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com

